Question special
Lead Moderator

Since enrollment in ABSORB III was restricted to patients with relatively stable symptoms and noncomplex coronary lesions, it is likely that results from this study cannot be generalized (as mentioned). What are the main contraindications when considering loosening the patient enrollment criteria? Is there an excluded population that may benefit from this study?